Figure 2. Blood Pressure Development During 12-Month Follow-up After Starting Erenumab or Fremanezumab.
Data presented in mean ± 95% CI. Asterisks present significant change compared with baseline: ***p < 0.001.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.